Breadcrumbs

SHIVERS-II study update on COVID-19

Get in touch

If you have any questions regarding this study, use the contact details below

or email

Study Update: COVID-19

As well as continuing our essential work researching influenza, the SHIVERS-II study is expanding to include testing for the SARS-CoV virus (causing the COVID-19 infection).

SHIVERS-II will play an important role in the fight against COVID-19 in New Zealand and around the world. We’re inviting you to be part of finding the solution to provide better public health measures and develop a vaccine to fight the virus.

What does this mean for you?

Your participation in SHIVERS-II is crucial to developing a global solution.

In addition to influenza testing, we will include testing of the SARS-CoV-2 virus for SHIVERS-II participants and those taking part in the household sub-study.

Supported by the US National Institutes of Health as well as the New Zealand government as a key essential service, this initiative aims to answer critical scientific questions to fill in the global knowledge gaps.

Research questions include:
• What kinds of symptoms and how long do they last if someone is infected?
• How many infected people would have only mild or no symptoms? Can these people infect others?
• What is the immune response against a COVID-19 infection?
• What kinds of immune responses in the elderly that make them more prone to severe COVID-19?
• How many household members would get infected after being exposed to the first household member with a COVID-19 infection? How long does it take this to happen?

 
Changes in SHIVERS study processes to protect you from COVID

The SHIVERS-II study is going to include testing for the SARS-CoV-2 virus in addition to the influenza virus.

To protect participants and our nursing team from the SARS-CoV-2 virus, our study activities will have some changes that we are working through.

Self Swabbing 

Changes in SHIVERS study processes to protect you from COVID


To protect participants and our nursing team from the SARS-CoV-2 virus our study processes are changing and we are introducing self swabbing.
Nurses will continue to take swabs in a situation where self-swabbing is not feasible. Nurses will also take swabs during a validation trial by running a nurse-swab and a self-swab in parallel to be sure self-swab is a valid method in our study.